GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments

GSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, a senior research executive said at Guggenheim's Healthcare Innovation Conference.